XENETIC BIOSCIENCES, INC. Long-term Line of Credit
XENETIC BIOSCIENCES, INC. (XBIO) had Long-term Line of Credit of $160.00 thousand as of 2013-11-30, per its 10-Q filed 2014-01-10.
Discontinued › Balance Sheet › Liabilities
us-gaap:LineOfCredit · last filed 2014-01-10
- 2013-11-30: Long-term Line of Credit $160.00K.
| Period end | Long-term Line of Credit |
|---|---|
| 2013-11-30 | $160.00K 10-Q · filed 2014-01-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |